<DOC>
	<DOCNO>NCT00073892</DOCNO>
	<brief_summary>RATIONALE : PI-88 may stop growth cancer stop blood flow tumor . PURPOSE : Phase I/II trial study effectiveness PI-88 treating patient advanced malignancy ( cancer ) stage IV melanoma .</brief_summary>
	<brief_title>PI-88 Treating Patients With Advanced Malignancy ( Cancer ) Stage IV Melanoma</brief_title>
	<detailed_description>OBJECTIVES : Phase I - Determine maximum tolerate dose PI-88 patient advanced malignancy . - Determine safety tolerability drug patient . Phase II - Determine progression-free survival time progression patient stage IV melanoma treat drug . - Determine biological activity drug patient . OUTLINE : This open-label , dose-escalation study . - Phase I ( part 1 2 ) : - Part 1 : Patients receive PI-88 subcutaneously ( SC ) daily day 1-4 15-18 . Cohorts 3-6 patient receive escalate dos PI-88 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Once MTD determine part I , effect dose frequency determine patient part II . - Part 2 : Patients receive PI-88 SC daily day 1-4 , 8-11 , 15-18 , 22-25 dose base MTD determine part 1 . Cohorts 3 patient receive escalate dos PI-88 MTD frequency determine . - Phase II ( patient metastatic melanoma ) : Patients receive PI-88 phase I , part 2 MTD . Treatment phase repeat every 28 day absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 18-69 patient ( 18-30 phase I [ part 1 ] , 6-9 phase I [ part 2 ] , 25-30 phase II ) accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Phase I Histologically cytologically confirm malignancy No effective treatment available OR fail prior therapy No prior concurrent symptomatic know CNS involvement brain meningeal metastases Phase II Diagnosis stage IV melanoma Metastatic disease must measurable No effective treatment available OR fail prior therapy Asymptomatic brain metastasis allow provided patient steroid PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 OR Karnofsky 70100 % Life expectancy At least 3 month Hematopoietic Neutrophil count great 1,500/mm^3 Platelet count great 100,000/mm^3 Negative serotonin release assay test antiheparin antibodies No abnormal bleeding tendency No history heparininduced thrombocytopenia No history immunemediated thrombocytopenia No history thrombolytic thrombocytopenic purpura No history platelet disease Hepatic Bilirubin less 1.5 time upper limit normal ( ULN ) AST ALT great 2 time ULN ( 5 time ULN liver metastasis present ) PTT normal ( 2034 sec ) PT le 1.5 time ULN Renal Creatinine clearance great 60 mL/min OR Glomerular filtration rate great 60 mL/min Cardiovascular No myocardial infarction within past 3 month No stroke within past 3 month No congestive heart failure within past 3 month Gastrointestinal No history acute chronic gastrointestinal bleeding within past 2 year No inflammatory bowel disease Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No AIDSrelated illness No serious infection within past 4 week No history alcohol , drug , substance abuse No history allergy and/or hypersensitivity anticoagulants/thrombolytic agent ( e.g. , heparin ) No risk bleed due open wound plan surgery No clinically significant nonmalignant disease No uncontrolled infection Inclusion Criteria Current diagnosis metastatic melanoma , effective therapy available fail . Measurable disease . Metastatic lesion measurable MRI CT , cutaneous lesion physical examination . Biopsiable Lesion Group : Must least one biopsiable lesion bidimensionally measurable previously unirradiated . Ageâ‰¥ 18 year . Have voluntarily give write informed consent participate study . Performance status : ECOG 0 2 ( Karnofsky 70 100 % ) . Life expectancy least 3 month . Neutrophil count &gt; 1.5 x 109/L ( 1,500/mm3 ) . Platelet count &gt; 100 x 109/L ( 100,000/mm3 ) . APTT normal ( 20 34 sec ) . PT &lt; 1.5 x ULN . Calculated creatinine clearance , use CockcroftGault formula , &gt; 60 mL/min . If 60 mL/min , GFR &gt; 60 mL/min determine EDTA DTPA scan . Bilirubin &lt; 1.5 x ULN . AST ALT 2 x ULN ; except presence liver metastases ; 5 x ULN . Exclusion Criteria Current symptomatic central nervous system involvement , active brain meningeal metastasis . Concomitant use aspirin ( &gt; 100 mg/day ) , nonsteroidal antiinflammatory drug ( exception COX2 inhibitor ) , heparin , low molecular weight heparin warfarin ( &gt; 1 mg/day ) ongoing anticipate study period . Lowdose aspirin ( 100 mg/day less ) lowdose warfarin ( 1 mg/day less ) permit . Heparin low molecular weight heparin within previous 2 week . Chemotherapy , investigational therapy hormonal therapy previous 4 week . Radiotherapy major bone marrow bear area pelvis , femoral head , lumbarsacral spine , within previous 4 week . Radiotherapy sit within previous 2 week . History allergy and/or hypersensitivity anticoagulants/thrombolytic agent , especially heparin . History heparininduced thrombocytopenia , immune mediate thrombocytopenia , thrombotic thrombocytopenic purpura and/or platelet disease , laboratory evidence antiheparin antibody . Myocardial infarction , stroke congestive heart failure within previous 3 month History acute chronic gastrointestinal bleeding within previous two year , inflammatory bowel disease , abnormal bleeding tendency , patient risk bleed due open wound plan surgery . Uncontrolled infection serious infection within previous 4 week . Clinically significant nonmalignant disease . Known AIDSrelated illness HIV positive . Women pregnant , breast feeding , childbearing potential pregnancy could exclude . History abuse alcohol , drug substance . Not recovered major surgery conduct prior study . PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy More 4 week since prior chemotherapy Endocrine therapy More 4 week since prior hormonal therapy Radiotherapy More 2 week since prior radiotherapy More 4 week since prior radiotherapy major bonemarrow bear area ( e.g. , pelvis , femoral head , lumbarsacral spine ) Concurrent palliative radiotherapy allow Surgery Recovered prior major surgery No concurrent surgery Other More 2 week since prior heparin lowmolecular weight heparin More 4 week since prior investigational therapy No concurrent investigational drug No concurrent antineoplastic therapy No concurrent aspirin aspirincontaining medication No concurrent nonsteroidal antiinflammatory drug Concurrent cyclooxygenase2 inhibitor allow No concurrent heparin lowmolecular weight heparin No concurrent warfarin warfarincontaining medication No concurrent anticoagulant medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>